Status:

RECRUITING

A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants

Lead Sponsor:

Juro Sciences Inc.

Conditions:

Health Participants

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy ad...

Eligibility Criteria

Inclusion

  • Healthy Japanese or white male and female participants aged between 18 and 45 years at the time of consent.
  • Participants who agree to use contraception during a specified period.
  • Participants with a Body Mass Index (BMI) of at least 18.0 kg/m2 and less than 32.0 kg/m2.
  • Participants who are judged to be healthy by the principal (or sub-) investigator.
  • Participants must understand the methods and compliance requirements of this study and must give his/her free and voluntary written consent to participate in this study.

Exclusion

  • Participants with clinically relevant symptoms, diseases, or pre-existing conditions.
  • Participants with extensive skin findings on the abdomen.
  • Participant who has used or will use prescription drugs, non-prescription drugs or products containing herbal medicines within a specified period
  • Participants whose normal weekly alcohol intake exceeds 150 g.
  • Habitual consumers of caffeine-containing beverages who are likely to experience symptoms if they stop.
  • Smokers or those who have smoked or used other nicotine-containing products within 6 months.
  • Participants who participated in a clinical trial and took a new active pharmacological ingredient within a specified period.
  • Participants who have undergone surgery within 4 weeks.
  • Pregnant or lactating women.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2026

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT07167914

Start Date

September 1 2025

End Date

April 1 2026

Last Update

September 11 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sumida Hospital

Tokyo, Japan

A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants | DecenTrialz